Related Experiment Video
Updated: May 7, 2026

Ocular Therapeutic Delivery and Advanced Tissue Retrieval in Adult Rats
Published on: May 23, 2025
Plasma and ocular prednisolone disposition after oral treatment in cats
María J Del Sole1, Paula Schaiquevich, Marcelo A Aba
1Hospital de Pequeños Animales, CIVETAN-CONICET, Facultad de Ciencias Veterinarias (UNCPBA), Campus Universitario, Paraje Arroyo Seco s/n, 7000 Tandil, Buenos Aires, Argentina ; Laboratorio de Farmacología, CIVETAN-CONICET, Facultad de Ciencias Veterinarias (UNCPBA), 7000 Tandil, Argentina.
Objective:
To evaluate the plasma and aqueous humor disposition of prednisolone after oral administration in cats.
Methods:
Six cats were administered with a single oral dose of prednisolone (10 mg). Blood and aqueous humor samples were serially collected after drug administration. Prednisolone concentrations in plasma and aqueous humor were measured at 0.25, 0.5, 1.0, 1.5, 2.0, 3.0, 4.0, and 5.0 h after administration by a high-performance liquid chromatographic analytical method developed and validated for this purpose.
Results:
Mean ± standard error (SE) of maximum plasma prednisolone concentration (300.8 ± 67.3 ng/mL) was reached at 1 h after administration. Prednisolone was distributed to the aqueous humor reaching a mean peak concentration of 100.9 ± 25.5 ng/mL at 1.25 h after administration. The mean ± SE systemic and aqueous humor exposure (AUC) was 553.3 ± 120.0 ng h/mL and 378.8 ± 64.9 ng h/mL, respectively. A high AUC(aqueous humor)/AUC(plasma) ratio was observed (0.68 ± 0.13). The mean half-life time of elimination in plasma and aqueous humor was 0.87 ± 0.16 h and 2.25 ± 0.44 h, respectively.
Clinical Significance:
The observed high ratio between aqueous humor and plasma prednisolone concentrations indicates that extensive penetration of prednisolone to the anterior segment of the eye may occur. This is the first step that contributes to the optimization of the pharmacological therapeutics for the clinical treatment of uveitis.
Related Concept Videos
Ophthalmic Drug Delivery Systems
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

